Outlook Therapeutics, INC

Outlook Therapeutics announced the FDA approval of LYTENAVA (bevacizumab-vikg) as the first and only FDA-approved ophthalmic formulation for treating wet age-related macular degeneration (AMD).

Outlook Therapeutics' stockholders approved an increase in authorized common stock and the potential issuance of shares related to warrant exercises, alongside a potential reverse stock split.

Outlook Therapeutics has officially regained compliance with Nasdaq's minimum bid price requirement after maintaining a share price of $1.00 or greater for ten consecutive business days.

Outlook Therapeutics announced the FDA has accepted its resubmitted Biologics License Application for ONS-5010 (bevacizumab-vikg) for wet AMD, with a PDUFA goal date set for July 29, 2026.

Outlook Therapeutics announced the resubmission of its Biologics License Application (BLA) for ONS-5010/LYTENAVA to the U.S. FDA for the treatment of neovascular age-related macular degeneration (nAMD).

Outlook Therapeutics, Inc. has entered into a securities purchase agreement for a registered direct offering of 8,539,709 shares of common stock.

Outlook Therapeutics reports Q2 2026 financial results, highlighting ongoing commercialization in Europe and continued regulatory efforts for ONS-5010 in the U.S. amid going concern warnings.

Outlook Therapeutics reports initial European revenue for LYTENAVA but faces substantial doubt about its ability to continue as a going concern, necessitating further financing.

Outlook Therapeutics resubmitted its BLA for ONS-5010/LYTENAVA and is awaiting an FDA decision by August 27, 2025, while preparing for a potential EU/UK launch in Q2 2025.

Outlook Therapeutics reports a net income of $17.4 million for the quarter ended December 31, 2024, while navigating financial uncertainties and pursuing regulatory approval for its lead product candidate, LYTENAVA.

Outlook Therapeutics announced its Q3 2024 financial results, highlighted the European and UK marketing authorizations for LYTENAVA, and provided updates on its ongoing clinical trials for ONS-5010.

Outlook Therapeutics reported a significant net loss for the second quarter of 2024 and faces substantial doubt about its ability to continue as a going concern, despite a positive opinion from the European Medicines Agency for its lead product candidate.

Outlook Therapeutics received a second Complete Response Letter from the FDA for its wet AMD treatment, ONS-5010/LYTENAVA, citing insufficient evidence of effectiveness, despite recent EU and UK market authorizations.

Outlook Therapeutics files an amendment to its Form 10-K to include information required by Part III, which was previously omitted.

Outlook Therapeutics reports its fiscal year 2024 results, highlighting the European approval of ONS-5010/LYTENAVA and ongoing efforts to secure U.S. approval, while also addressing financial challenges and a recent workforce reduction.

Outlook Therapeutics has filed an amendment to its annual report on Form 10-K to include information previously omitted from Part III of the original filing.

Faisal Ghiath Sukhtian, a Director of Outlook Therapeutics, Inc., purchased 95,398 shares of common stock on July 29, 2026 for $1.05 per share.

Lawrence A Kenyon, Chief Financial Officer and a Director of Outlook Therapeutics, Inc., received 210,078 shares of common stock on July 21, 2026.

Robert Charles Jahr, Chief Executive Officer and a Director of Outlook Therapeutics, Inc., received 100,000 shares of common stock on July 21, 2026.

Director Yezan Haddadin purchased 29,000 shares of Outlook Therapeutics, Inc. common stock at an average price of $0.8326.

GMS Ventures & Investments increases its stake in Outlook Therapeutics through a $5 million share purchase and a significant repricing of existing warrants.

Outlook Therapeutics, Inc. reports a Form 4 filing detailing a significant stock acquisition by Director Faisal Ghiath Sukhtian.

Outlook Therapeutics seeks shareholder approval for share issuance, authorized share increase, and a reverse stock split.

Outlook Therapeutics, Inc. has filed a definitive proxy statement with the SEC, signaling upcoming shareholder matters.

Outlook Therapeutics, Inc. announces its 2026 Annual Meeting of Stockholders to be held on March 10, 2026, to vote on director elections, auditor ratification, and executive compensation.

Outlook Therapeutics is asking stockholders to approve a convertible note share issuance and an increase in authorized shares at its upcoming annual meeting.

Outlook Therapeutics is asking stockholders to approve the 2024 Equity Incentive Plan at a special meeting on August 12, 2024, to continue attracting and retaining talent.

GMS Ventures and Investments has invested $5 million in Outlook Therapeutics through a registered direct offering, increasing its beneficial ownership to 22.9%.

GMS Ventures and Ghiath M. Sukhtian have significantly increased their beneficial ownership in Outlook Therapeutics, Inc. to 50.3% after investing $6 million in the company's May 2025 Public Offering.

GMS Ventures and Ghiath M. Sukhtian have updated their beneficial ownership in Outlook Therapeutics, Inc. to 41.6% following an amendment to the Issuer's Restated Certificate of Incorporation.

GMS Ventures and Ghiath M. Sukhtian have updated their beneficial ownership in Outlook Therapeutics, Inc. to 38.6% following the exercise of existing warrants and the receipt of new inducement warrants.

Intracoastal Capital LLC and its principals have reported a 4.99% beneficial ownership stake in Outlook Therapeutics following a recent securities purchase agreement.

Sphera Funds Management Ltd. and its affiliates reported a 4.69% beneficial ownership stake in Outlook Therapeutics, Inc., primarily through exercisable warrants.

Empery Asset Management, along with Ryan M. Lane and Martin D. Hoe, reported a 4.99% beneficial ownership stake in Outlook Therapeutics, Inc., primarily through warrants.

Tang Capital Management and affiliates report a 3.4% passive stake in Outlook Therapeutics, Inc., holding 1.5 million shares issuable upon warrant exercise.

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, filed an amendment to their Schedule 13G, disclosing a continued beneficial ownership of 4.99% in Outlook Therapeutics, Inc.

Empery Asset Management, LP, along with its managing members Ryan M. Lane and Martin D. Hoe, reported a 7.57% beneficial ownership stake in Outlook Therapeutics, Inc. common stock.